Sorrento Therpt Cmn (SRNE) 6.66 $SRNE Sorrento

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 9:03 AM

Sorrento Therpt Cmn (SRNE) 6.66 $SRNE

Sorrento Therapeutics to Present at Two Upcoming Conferences in New York City
PR Newswire - Tue Aug 30, 3:01PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"

, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, and other unmet medical needs, announced today that it will be presenting at two upcoming conferences in New York City.
SRNE: 6.66 (+0.10)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Sorrento Therapeutics, Inc. - SRNE
ACCESSWIRE - Tue Aug 23, 8:29AM CDT
NEW YORK, NY / ACCESSWIRE / August 23, 2016 / Levi & Korsinsky announces it has commenced an investigation of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) concerning possible breaches of fiduciary duty by the board of directors of the company. To obtain additional information, go to:
SRNE: 6.66 (+0.10)

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sorrento Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
PR Newswire - Tue Aug 23, 6:11AM CDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Sorrento Therapeutics, Inc. (NASDAQ: SRNE).
SRNE: 6.66 (+0.10)

Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur Pharmaceuticals, Inc. to Further Deepen its Pain Management Pipeline
PR Newswire - Mon Aug 15, 5:34PM CDT
Scintilla Pharmaceuticals, Inc. ("Scintilla"

, a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"

, has entered into a binding term sheet to acquire Semnur Pharmaceuticals, Inc. ("Semnur"

. Scintilla's lead program is resiniferatoxin ("RTX"

for the treatment of intractable cancer pain.
SRNE: 6.66 (+0.10)

Commit To Buy Sorrento Therapeutics At $5, Earn 15.3% Annualized Using Options
StockOptionsChannel.com - Mon Aug 15, 10:33AM CDT
Investors eyeing a purchase of Sorrento Therapeutics Inc stock, but cautious about paying the going market price of $6.80/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
SRNE: 6.66 (+0.10)

Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene, to Join Sorrento as Chief Medical Officer and President of Clinical Development
PR Newswire - Mon Aug 15, 8:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"

, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, today announced that Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene Corporation (NASDAQ: CELG; "Celgene"

, has been appointed to the position of Chief Medical Officer and President of Clinical Development.
SRNE: 6.66 (+0.10), CELGZ: 1.16 (-0.03), CELG: 106.74 (unch)

Medovex Corp. Completes Financing Led by Sorrento Therapeutics, Inc.
Marketwire Canada - Tue Aug 09, 9:23AM CDT
ATLANTA, GA--(Marketwired - Aug 9, 2016) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced the successful completion of a $1,150,000 financing transaction led by an investment from Sorrento Therapeutics, Inc. (NASDAQ: SRNE).
MDVX: 1.40 (-0.03), SRNE: 6.66 (+0.10)

Scintilla Pharmaceuticals, a Subsidiary of Sorrento Therapeutics, to Acquire SCILEX Pharmaceuticals to Add a Late-Stage Asset to Bolster its Pain Management Business
PR Newswire - Mon Aug 08, 8:00AM CDT
Scintilla Pharmaceuticals, Inc. ("Scintilla"

, a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"

, has entered into a binding term sheet to acquire SCILEX Pharmaceuticals, Inc. ("SCILEX"

. Scintilla's lead program is resiniferatoxin ("RTX"

for the treatment of intractable cancer pain.
SRNE: 6.66 (+0.10)

Sorrento to Form Joint Venture with CHA Biotech to Develop and Commercialize Natural Killer Cell Therapies
PR Newswire - Tue Aug 02, 8:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"

, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has entered into a binding term sheet to create a joint venture ("JV"

with CHA Biotech Co. , LTD, (KOSDAQ: CHA; "CBT"

of South Korea to develop and commercialize proprietary Chimeric Antigen Receptor ("CAR"

modified cellular therapies based on CBT's Activated Killer Cell ("AKC"

technology and five of Sorrento's CARs for all disease conditions, including oncology and infectious diseases. The JV covers products on a global basis with the exception of the Greater Chinese market.
SRNE: 6.66 (+0.10)

Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
PR Newswire - Mon Aug 01, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"

, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today the appointment of Yue Alexander Wu, Ph.D to its Board of Directors (the "Board"

. Dr. Wu will also serve as a member of the Compensation Committee and Audit Committee of the Board. Doug Ebersole has resigned as a member of the Board for personal reasons.
SRNE: 6.66 (+0.10)

Sorrento Closes $150 Million Private Placement Investments
PR Newswire - Wed Jun 08, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"

, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs announced today that it has closed on $150 million related to the private placements of common stock and warrants previously announced by the company on April 4, 2016.
SRNE: 6.66 (+0.10)

Sorrento and 3SBio Announce CAR-T Joint Venture in China
PR Newswire - Tue Jun 07, 8:04AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"

, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today its subsidiary TNK Therapeutics, Inc. ("TNK"

has entered into a joint venture agreement ("JVA"

with Shenyang Sunshine Pharmaceutical Company Ltd ("3SBio"

to develop and commercialize proprietary immunotherapies, including those developed from, including or using TNK's chimeric antigen receptor T cell ("CAR-T"

technology targeting carcinoembryonic antigen ("CEA"

positive cancers. 3SBio is a leading China-based biotechnology company focused on discovering, developing, manufacturing, and commercializing biopharmaceutical products.
SRNE: 6.66 (+0.10)

Sorrento Therapeutics to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu May 26, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"

, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that Dr. Henry Ji, President and CEO, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 in New York, NY. The Sorrento presentation is scheduled to begin at 9:00am EDT.
SRNE: 6.66 (+0.10)

Sorrento Announces Positive Data from a Combined Phase 2 & 3 Clinical Study of STI-004, an Anti-IgE Biosimilar Antibody
PR Newswire - Mon May 16, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"

, an antibody-centric, clinical-stage biopharmaceutical company developing new therapies for cancer and other unmet medical needs announced that its partner, Mabtech Ltd., has successfully completed a combined Phase 2 & 3 clinical study in China for STI-004, a biosimilar antibody for Omalizumab (Xolair®). STI-004 met its primary endpoint in a multicenter, randomized, double-blind, placebo-controlled clinical trial.
SRNE: 6.66 (+0.10)

Wildcat Capital Issues Letter to Board of Sorrento Therapeutics
PR Newswire - Fri May 06, 8:00AM CDT
Wildcat Capital Management LLC ("Wildcat"

, whose clients hold an ownership stake of 6.5% of the common stock of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (the "Company" or "Sorrento"

, today sent a letter to the Company's Board of Directors (the "Board"

urging the Board to take specific actions to remedy the ongoing destruction of significant shareholder value. In particular, the letter calls for the Board to immediately terminate and replace Dr. Henry Ji as Chief Executive Officer and to stop recently announced financing transactions to avoid further dilution to the existing shareholders. The letter also calls for the appointment of three Wildcat nominees to the Board to lead a special committee authorized to initiate a sales process for the Company.
SRNE: 6.66 (+0.10)

Sorrento closes private placement with Yuhan Corporation
PR Newswire - Mon May 02, 10:24AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"

, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has closed its previously announced private placement of common stock and warrants with Yuhan Corporation (000100.KS; "Yuhan"

of South Korea for gross proceeds of $10 million.
SRNE: 6.66 (+0.10)

Sorrento to Present at 2 Upcoming Conferences in New York City
PR Newswire - Mon May 02, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Gunnar F. Kaufmann, Ph.D., Senior Vice President, Immunotherapy, & Head of Research and Global Partnerships, will present at 2 upcoming conferences in New York City:
SRNE: 6.66 (+0.10)

Sorrento to Present at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
PR Newswire - Thu Apr 14, 6:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today 3 poster presentations at the upcoming AACR Annual Meeting 2016 at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA, April 16 - 20, 2016.
SRNE: 6.66 (+0.10)

Sorrento to Present at the Jefferies Immuno-Oncology Summit
PR Newswire - Wed Apr 06, 11:53AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today that Gunnar F. Kaufmann, Ph.D., Senior Vice President, Immunotherapy, & Head of Research and Global Partnerships, will present at the Jefferies Immuno-Oncology Summit on Thursday, April 7, 2016 from 7:55 am to 8:20 am EDT. The conference will take place at the Boston Harbor Hotel in Boston, MA.
SRNE: 6.66 (+0.10)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Appy Pie Secures Patent for AI Driven App Building

A New Dawn in App Creation You ever think about a world where creating an app is as straightforward as chatting with an old buddy? Well, that future's knocking at the door, courtesy of Appy Pie. They're ruffling feathers with a shiny new U.S. patent promising just that—apps whipped into shape by a bit of chitchat with their AI-powered platform. It's got folks scratching...

Perkins Rolls Out Mahjong to Revive Family Bonds

Perkins Ditches the Phones, Sparks True Connection No doubt about it, folks—Perkins Restaurant & Bakery has cooked up something special to bring families back to the table. Not just for pancakes or pies this time, but for a little classic game action with their limited-edition Mahjong set. Love it or leave it, this is Perkins tapping into the magic of togetherness...

Gray's Rise in ENR Rankings Highlights Sector Dominance

Gray's Outstanding Reputation in the Construction Arena Nothing says “we're on top of our game” like snatching top slots in industry rankings, and that's precisely what Gray, the construction and engineering heavyweight, has managed to do. This firm recently secured impressive spots across ten different categories in the prestigious Engineering News-Record (ENR) Top...

Kansas Marijuana DUI Laws: What Drivers Must Know

Navigating the Legal Maze of Marijuana DUIs Marijuana DUI, ever heard of it? Many folks in Kansas might just find themselves scratching their heads. While booze clearly shouts 'DUI' when you hit the road sauced, the green stuff doesn’t dodge that same bullet. You better believe it, Kansas doesn’t mess around when it comes to drugs behind the wheel, and marijuana is...

Once Upon a Coconut Supports Breast Cancer Cause

Supporting Breast Cancer Awareness When a coconut water brand shifts to pink, it's not just about changing colors—it's a signal of commitment. Every October, the world paints itself pink to stand against breast cancer, and Once Upon a Coconut is no different. This year, they're diving headfirst into Breast Cancer Awareness Month with their limited-edition pink cans, all...

Nailah Thorbourne's Vlair Shapewear: Fashion Freedom

Fashion with a Punch: Nailah Thorbourne's New Venture You'd think from the way the fashion industry's been humming along that someone would've cracked the code on shapewear a long time ago, right? But alas, it takes Nailah Thorbourne to step out of Brick & Lace's spotlight and into this shapely market with Vlair Shapewear. Apparently, what most overlooked in comfort, she...

J.P. Morgan, Thunes Partner for Global Payment Integration

You don't need a crystal ball to see J.P. Morgan's playing the long game by teaming up with Thunes. In this world, where cash is digital and the reach is global, it's all about speed and scale—brushing elbows with the right partners makes all the difference. Sometimes it's about knowing when to hitch your wagon to a reliable workhorse, especially when global commerce is...

NUS Unveils eLuminator: A Leap for Robotics & Healthcare

Game-Changing Electronic Skin From NUS It's not every day you come across tech that could shake up multiple industries, but that's just what the National University of Singapore has cooked up with their latest brainchild—the eLuminator. This ain't your everyday wearable tech. We're talking a skin-like device that can both detect and show touch in real-time, no fiddly...

PVOLVE Expands Reach with New Franchises in 2026

The PVOLVE Fitness Craze Picks Up Momentum Seriously, if you hadn’t heard of PVOLVE before, now might be the time to get your ears in tune—and maybe consider hitting up one of their studios. They’ve been on an expansion tear, with franchise deals popping up like daisies in Washington and Wisconsin. It's the two new spots in Tacoma and Brookfield that are grabbing...

Klydoclock's Bold Move: Licensing International Boost

Revolutionizing Timekeeping with Art There’s this clock outfit, Klydoclock, that’s flipping the script on how we see time and art melding together. You see, they’ve taken those static old tick-tock reminders of the hour and juiced 'em up with animated art, turning your wall clock into something more akin to a mini art exhibit right in your living room. Ever heard of...